Demoxytocin

Demoxytocin
Clinical data
Routes of
administration		 Buccal
ATC code H01BB01 (WHO)
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
Synonyms ODA-914;
1-mercaptopropionate-
oxytoxin
CAS Number 113-78-0 YesY
PubChem (CID) 449224
ChemSpider 395815 N
ECHA InfoCard 100.003.668
Chemical and physical data
Formula C43H65N11O12S2
Molar mass 992.1727 g/mol
3D model (Jmol) Interactive image

Demoxytocin (INN) (brand names Sandopart, Odeax, Sandopral), also known as desaminooxytocin or deaminooxytocin, as well as 1-(3-mercaptopropanoic acid)oxytocin ([Mpa1]OT), is an oxytocic peptide drug and synthetic analogue of oxytocin that is marketed in several European countries, including Italy, Czechoslovakia, and Poland.[1][2][3] It has the amino acid sequence Mpa-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (Mpa = β-mercaptopropionic acid),[4] and is an analogue of oxytocin wherein the leading cysteine is replaced with β-mercaptopropionic acid.[4] Demoxytocin has similar activities as oxytocin,[5] but is more potent and has a longer half-life in comparison.[3][4] Unlike oxytocin, which is given via intravenous injection, demoxytocin is administered as a buccal tablet formulation.[3][6] It is used to induce labor,[4] promote lactation,[3] and to prevent and treat puerperal (postpartum) mastitis (breast inflammation).[7] The drug was first synthesized in 1960 and was introduced into clinical practice in 1971 by Sandoz.[2][8]

See also

References

  1. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 301–. ISBN 978-3-88763-075-1.
  2. 1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 349–. ISBN 978-1-4757-2085-3.
  3. 1 2 3 4 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 93–. ISBN 978-94-011-4439-1.
  4. 1 2 3 4 Christine Bladon (3 April 2002). Pharmaceutical Chemistry: Therapeutic Aspects of Biomacromolecules. John Wiley & Sons. pp. 61–. ISBN 978-0-471-49637-3.
  5. ↑ C.J. van Boxtel; B. Santoso; I.R. Edwards (6 August 2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition. IOS Press. pp. 389–. ISBN 978-1-60750-345-3.
  6. ↑ Tom K. A. B. Eskes; Mieczyslaw Finster (22 October 2013). Drug Therapy During Pregnancy. Elsevier. pp. 185–. ISBN 978-1-4831-6298-0.
  7. ↑ Sternadel Z, Gerkowicz J (1979). "[Use of deaminooxytocin (Sandopart) in the prevention and treatment of puerperal mastitis]". Ginekol. Pol. (in Polish). 50 (5): 413–6. PMID 468056.
  8. ↑ Erhard Gross; Johannes Meienhofer (10 May 2014). Major Methods of Peptide Bond Formation: The Peptides Analysis, Synthesis, Biology. Elsevier. pp. 53–. ISBN 978-1-4832-1796-3.


This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.